Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial

Josef S Smolen, André Beaulieu, Andrea Rubbert‐Roth et al. · The Lancet · 2008 · 1.4K citations

Medicine, Immunology, Pharmacology +16

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

Paul Emery, Edward Keystone, Hans‐Peter Tony et al. · Annals of the Rheumatic Diseases · 2008 · 1.1K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Interleukin‐6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease‐modifying antirheumatic drugs: The tocilizumab in combination with traditional disease‐modifying antirheumatic drug therapy study

Mark C. Genovese, James D. McKay, Eduardo Mysler et al. · Arthritis & Rheumatism · 2008 · 858 citations

Medicine, Pharmacology, Pharmacotherapy +16

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

Graeme Jones, Anthony Sebba, Jianhui Gu et al. · Annals of the Rheumatic Diseases · 2009 · 809 citations · Full text

Medicine, Immunology, Pharmacotherapy +17

Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab

Jun Hashi­moto, N. Miyasaka, Kazuhiko Yamamoto et al. · Annals of the Rheumatic Diseases · 2007 · 741 citations · Full text

Medicine, Immunology, Pharmacotherapy +16